ImageneBio, Inc.

IMASEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1835579

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$3.5M	$9.2M	$15.6M	$31.0M	$9.2M
Research and Development Expense	$32.1M	$59.7M	$64.3M	$47.1M	$44.8M
Operating Expenses	$40.5M	$84.6M	$86.5M	$65.1M	$53.7M
Operating Income (Loss)	-$37.0M	-$75.4M	-$70.9M	-$34.1M	-$44.5M
Nonoperating Income (Expense)	$445.0K	$7.1M	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$36.6M	-$68.3M	-$68.8M	—	—
Income Tax Expense (Benefit)	$13.0K	-$162.0K	-$162.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$15.9M	$192.1M	$172.3M	$247.9M	$168.4M
Assets, Current	$12.5M	$178.7M	$160.0M	$236.5M	$166.0M
Cash and Cash Equivalents, at Carrying Value	$12.1M	$119.9M	$59.9M	$232.2M	$162.5M
Liabilities	$17.4M	$22.3M	$25.3M	$40.0M	$63.5M
Liabilities, Current	$17.2M	$14.2M	$21.5M	$27.2M	$28.3M
Accounts Payable, Current	$5.3M	$2.1M	$2.1M	$2.4M	$2.1M
Stockholders' Equity Attributable to Parent	-$126.1M	$147.0M	$207.9M	-$101.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$21.3M	-$79.7M	-$74.1M	-$60.3M	-$37.8M
Net Cash Provided by (Used in) Investing Activities	$11.1M	$64.1M	-$99.3M	-$1.8M	$2.9M
Net Cash Provided by (Used in) Financing Activities	$6.9M	$76.0M	$1.1M	$131.7M	$116.2M
Payments to Acquire Property, Plant, and Equipment	—	$414.0K	$1.4M	$1.8M	$766.0K
Payments for Repurchase of Common Stock	—	$663.0K	$663.0K	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)